ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock



Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity	
Current assets	2,609,000,000		3,561,000,000		2,713,000,000		
Common stock capital		2,000,000		2,000,000		2,000,000	
Fixed assets	7,502,000,000		8,691,000,000		12,504,000,000		
Equity capital of a company		5,745,000,000		6,599,000,000		10,740,000,000	
Cash and cash equivalents	1,048,000,000		2,011,000,000		1,232,000,000		
Accrued liabilities		0		0		0	
Other assets	-		-		-		
Current liabilities		1,570,000,000		2,773,000,000		1,093,000,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		2,796,000,000		2,880,000,000		3,384,000,000	
Different income		-		-		-	
Other liabilities		620,000,000		649,000,000		915,000,000	
Total assets	10,111,000,000	10,111,000,000	12,252,000,000	12,252,000,000	15,217,000,000	15,217,000,000	

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	12,010	11,500	9,800
Equity ratio	56.82%	53.86%	70.58%
Debt-equity ratio	76.00%	85.66%	41.69%

Others

	2023	2022	2021
Tax Expense Rate	-3.94%	-1.57%	13.80%

ILLUMINA INC.

ISIN: US4523271090 WKN: 452327109 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	4,504,000,000	4,584,000,000	4,526,000,000
Net income	-1,161,000,000	-4,404,000,000	762,000,000
EBIT	-1,030,692,600	-4,056,122,700	887,071,500
Operating income before taxes	-1,117,000,000	-4,336,000,000	884,000,000
Cash Flow	477,000,000	392,000,000	545,000,000
Net interest income	-19,000,000	-15,000,000	-61,000,000
Research and development expenses	1,330,000,000	1,321,000,000	1,185,000,000
Income taxes	44,000,000	68,000,000	122,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	352,032	374,174	433,526

Board of Directors

Members of Management Board				
Stephen MacMillan	Chairman of Board of Directors			
Frances Arnold	Member of Board of Directors			
Gary Guthart	Member of Board of Directors			
Robert Epstein	Member of Board of Directors			
Scott Gottlieb	Member of Board of Directors			
Andrew Teno	Member of Board of Directors			
Caroline Dorsa	Member of Board of Directors			
Philip Schiller	Member of Board of Directors			
Scott Ullem	Member of Board of Directors			
Susan Siegel	Member of Board of Directors			
Jacob Thaysen	Chairman of Managing Board			
Carissa Rollins	Member of Executive Committee			
Joydeep Goswami	Member of Executive Committee			
Kathryne Reeves	Member of Executive Committee			
Steve Barnard	Member of Executive Committee			